NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT04266912 2025-11-25
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT05289856 2024-03-07
Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
Johannes Gutenberg University Mainz
Phase 2 Active not recruiting
NCT03891238 2024-02-01
ARIES
Consorzio Oncotech
Phase 2 Completed
NCT03000179 2022-04-14
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT04698213 2021-01-06
TIDE-A
Consorzio Oncotech
Phase 2 Unknown